Aptevo Reports Mipletamig Combination Therapy Enabled 21% of Frontline AML Patients to Advance to Potentially Curative Stem Cell Transplant
Aptevo reported that ten of 47 (21%) evaluable frontline AML patients treated with mipletamig plus venetoclax and azacitidine advanced to allogeneic stem cell transplant, a potentially curative option. By comparison, only 0.7% of patients receiving VEN+AZA alone underwent transplant in the pivotal Phase 3 VIALE-A trial, though cross-trial comparisons carry caveats around patient mix and design.
Key figures
- Drug Name
- mipletamig
- Phase Of Trial
- Phase 1b/2 (RAINIER)
- Transplant rate
- 21%
- Evaluable patients
- 47
- Patients to transplant
- 10
- Viale a transplant rate
- 0.7%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.